Multiple Myeloma Treatment and Symptoms trials
Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells, immune system cells in bone marrow that produce antibodies. Its prognosis, despite therapy, is generally poor, and treatment may involve chemotherapy and stem cell transplant. It is part of the broad group of diseases called hematological malignancies. Clinical features Because many organs can be affected by myeloma, the symptoms and signs are ...
Wikipedia - [full article]
Multiple Myeloma Clinical Trials
- Bortezomib and Liposomal Doxorubicin in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00088855 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00024466 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002678 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002556 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004088 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Dexamethasone With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00064038 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00021359 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00098475 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Previously Untreated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002548 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Phase III Randomized Study of Melphalan With or Without Holmium Ho 166 DOTMP Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00008229 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
- Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00040937 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Vaccine Therapy Plus GM-CSF in Treating Patients With Multiple Myeloma Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00002787 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Bortezomib in Combination with CC-5013 in Patients with Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00153933 - Active, not recruiting
Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple Myeloma
- Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
ClinicalTrials.gov Identifier: NCT00002850 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; Infection
- Antineoplaston Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003511 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00007995 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028600 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00054353 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049673 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00109902 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112879 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Melphalan and Radiation Therapy Followed By Dexamethasone and Thalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112827 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00114101 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00253578 - Recruiting
Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
- Melphalan and Amifostine Followed By Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00087321 - Not yet recruiting
Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- 8-Chloro-cyclic Adenosine Monophosphate in Treating Patients With Recurrent or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004902 - Completed
stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
- Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00022607 - Completed
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- CCI-779 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00079456 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00054158 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003146 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003493 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00033332 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon alfa in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005987 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00047203 - Completed
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Interleukin-12 in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003149 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00008268 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004072 - Completed
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003399 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003401 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Rituximab in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003554 - Completed
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Ice Chips Or Saline Mouth Rinse in Reducing Or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00118339 - Completed
oral complications of cancer and cancer therapy; Drug Toxicity; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Combination Chemotherapy and Interferon alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
ClinicalTrials.gov Identifier: NCT00002599 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis
ClinicalTrials.gov Identifier: NCT00002810 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
ClinicalTrials.gov Identifier: NCT00004040 - Active, not recruiting
stage II chronic lymphocytic leukemia; stage I multiple myeloma; stage II multiple myeloma; stage IV chronic lymphocytic leukemia; ...
- Beta Alethine in Treating Patients With Myeloma
ClinicalTrials.gov Identifier: NCT00006466 - Active, not recruiting
monoclonal gammopathy of undetermined significance; stage I multiple myeloma; stage II multiple myeloma; extramedullary plasmacytoma; ...
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017069 - Active, not recruiting
refractory plasma cell neoplasm; stage II multiple myeloma; stage III multiple myeloma
- Arsenic Trioxide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00014339 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; Quality of Life
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028886 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma
- FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00066638 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124605 - Active, not recruiting
unspecified adult solid tumor, protocol specific; refractory plasma cell neoplasm; stage III multiple myeloma; stage II multiple myeloma
- Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00084747 - Recruiting
stage II multiple myeloma; stage III multiple myeloma
- High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00064337 - Recruiting
primary systemic amyloidosis; stage II multiple myeloma; stage III multiple myeloma
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00085345 - Recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006232 - Completed
stage II multiple myeloma; stage III multiple myeloma
- Phase II Study of R115777 in Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00012350 - Completed
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00008242 - Completed
stage II multiple myeloma; stage III multiple myeloma
- Total-Body Irradiation, Busulfan, and Interferon alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003195 - Completed
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00243035 - Completed
Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
- CI-994 in Treating Patients With Advanced Myeloma
ClinicalTrials.gov Identifier: NCT00005624 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II
ClinicalTrials.gov Identifier: NCT00075829 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00483262 - Recruiting
Multiple Myeloma; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
- Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006184 - Recruiting
Multiple Myeloma
- Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
ClinicalTrials.gov Identifier: NCT00099047 - Not yet recruiting
Multiple Myeloma; monoclonal gammopathy of undetermined significance
- Evaluation of Cellular and Humoral Immunity Against the Idiotype in Multiple Myeloma Patients Undergoing Autologous Transplantation After Idiotype Vaccination in an Attempt to Decrease the Risk of Relapse
ClinicalTrials.gov Identifier: NCT00001562 - No longer recruiting
Multiple Myeloma
- Vincristine, DOXIL® (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00344422 - Active, not recruiting
M-Protein; Multiple Myeloma; Myeloma; Myeloma Proteins
- Bortezomib in Treating Patients With Newly Diagnosed High-Risk Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00075881 - Active, not recruiting
stage III multiple myeloma
- Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00060203 - Active, not recruiting
stage III multiple myeloma; refractory plasma cell neoplasm
- CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00056160 - Active, not recruiting
Multiple Myeloma
- Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006219 - Active, not recruiting
Multiple Myeloma
- Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002653 - Active, not recruiting
Multiple Myeloma
- Combined Bone Marrow and Kidney Transplant for Multiple Myeloma with Kidney Failure
ClinicalTrials.gov Identifier: NCT00062621 - Active, not recruiting
Kidney Failure, Chronic; Multiple Myeloma
- Epoetin alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
ClinicalTrials.gov Identifier: NCT00003341 - Active, not recruiting
Lymphoma; Leukemia; Multiple Myeloma
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00095680 - Active, not recruiting
Multiple Myeloma
- Mobilization of Stem Cells with AMD3100 in Multiple Myeloma Patients
ClinicalTrials.gov Identifier: NCT00103662 - Active, not recruiting
Multiple Myeloma
- Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
ClinicalTrials.gov Identifier: NCT00003163 - Active, not recruiting
Lymphoma; Multiple Myeloma
- A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
ClinicalTrials.gov Identifier: NCT00091624 - Active, not recruiting
Multiple Myeloma
- Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00080405 - Active, not recruiting
Multiple Myeloma
- Safety and efficacy of single-agent CC-5013 in subjects with relapsed and refractory multiple myeloma
ClinicalTrials.gov Identifier: NCT00065351 - Active, not recruiting
Multiple Myeloma
- Study of Combination PS-341 and Thalidomide in Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00083460 - Active, not recruiting
Multiple Myeloma
- Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00057564 - Active, not recruiting
Multiple Myeloma
- Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00103506 - Active, not recruiting
Multiple Myeloma
- Study of Oral SCIO-469 in Relapsed, Refractory Patients with Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00087867 - Active, not recruiting
Multiple Myeloma
Resources
- American Cancer Society
- Amyloidosis (MayoClinic)